ArticleBMC health services research2018

Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective.

Valentina Lorenzoni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.